Back to Directory
Eptinezumab
Performance & EnduranceAnti-CGRP monoclonal antibody for migraine prevention, IV formulation.
Key Benefits
- ✓Prevents migraines
- ✓IV quarterly dosing
- ✓Rapid onset (day 1)
- ✓Reduces monthly migraine days
- ✓Alternative to daily preventives
Dosing Information
Dosage Range
100-300 mg
Frequency
Every 3 months
Typical Duration
Ongoing
Detailed Protocol
Administered via intravenous infusion every 3 months in infusion center or office. Each infusion takes about 30 minutes. Prescription required.
About Eptinezumab
Eptinezumab (Vyepti) is a humanized monoclonal antibody that binds CGRP, preventing migraine attacks. While technically an antibody (not traditional peptide), it is peptide-based. First and only IV migraine preventive. FDA-approved.
Research Notes
FDA-approved in 2020 for migraine prevention. Only IV CGRP antibody. Studies show efficacy on day 1. Quarterly dosing more convenient than daily pills for some.
Potential Side Effects
- •Nasopharyngitis
- •Hypersensitivity reactions
- •Infusion site pain
- •Fatigue
- •Generally well tolerated
Always consult with a healthcare professional before starting any peptide therapy.